Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

CLLS

Cellectis ADR

Jul 26 • 04:00PM ET

2.30

Dollar change +0.25
Percentage change 12.20	%

Healthcare • Biotechnology • France • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Held by: APIE AVDE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.05	Insider Own	3.93%	Shs Outstand	71.75M	Perf Week	13.30%
Market Cap	165.81M	Forward P/E	-	EPS next Y	-0.56	Insider Trans	0.00%	Shs Float	69.26M	Perf Month	22.99%
Income	-65.35M	PEG	-	EPS next Q	-0.29	Inst Own	13.71%	Short Float	0.64%	Perf Quarter	-7.63%
Sales	5.14M	P/S	32.26	EPS this Y	64.21%	Inst Trans	-2.53%	Short Ratio	6.91	Perf Half Y	-16.67%
Book/sh	1.26	P/B	1.83	EPS next Y	11.89%	ROA	-25.90%	Short Interest	0.44M	Perf Year	0.00%
Cash/sh	2.96	P/C	0.78	EPS next 5Y	-	ROE	-76.82%	52W Range	0.96 - 3.77	Perf YTD	-25.32%
Dividend Est.	-	P/FCF	-	EPS past 5Y	1.69%	ROI	-36.07%	52W High	-39.05%	Beta	3.07
Dividend TTM	-	Quick Ratio	1.63	Sales past 5Y	42.86%	Gross Margin	-269.58%	52W Low	138.89%	ATR (14)	0.13
Dividend Ex-Date	-	Current Ratio	1.63	EPS Y/Y TTM	53.69%	Oper. Margin	-2023.96%	RSI (14)	59.39	Volatility	5.87% 4.86%
Employees	221	Debt/Eq	1.15	Sales Y/Y TTM	-70.98%	Profit Margin	-1270.39%	Recom	1.57	Target Price	6.57
Option/Short	Yes / Yes	LT Debt/Eq	1.00	EPS Q/Q	109.36%	Payout	-	Rel Volume	6.26	Prev Close	2.05
Sales Surprise	75.75%	EPS Surprise	124.24%	Sales Q/Q	3157.55%	Earnings	May 28 AMC	Avg Volume	64.14K	Price	2.30
SMA20	13.78%	SMA50	-1.74%	SMA200	-10.31%	Trades		Volume	401,524	Change	12.20%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-17-23	Initiated	Bryan Garnier	Buy	$6
May-18-22	Upgrade	Robert W. Baird	Neutral → Outperform	$10
Jan-06-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$39 → $16
Nov-30-21	Initiated	JMP Securities	Mkt Outperform	$20
Nov-08-21	Downgrade	William Blair	Outperform → Mkt Perform
Oct-08-21	Downgrade	Robert W. Baird	Outperform → Neutral	$39 → $10
Apr-28-21	Downgrade	Guggenheim	Buy → Neutral
Mar-16-21	Upgrade	Robert W. Baird	Neutral → Outperform	$23 → $39
Aug-19-20	Upgrade	Citigroup	Neutral → Buy	$15 → $32
May-12-20	Initiated	Robert W. Baird	Outperform	$20
Mar-06-20	Downgrade	Goldman	Neutral → Sell	$15 → $11
Oct-30-19	Resumed	Guggenheim	Buy	$28
Aug-09-19	Initiated	BTIG Research	Buy	$37
May-24-19	Resumed	Citigroup	Neutral	$22
Mar-14-19	Initiated	William Blair	Outperform
Dec-19-18	Initiated	Goldman	Neutral
Jul-16-18	Initiated	Barclays	Overweight	$50
Mar-16-18	Initiated	Guggenheim	Neutral
Sep-05-17	Reiterated	Wells Fargo	Outperform	$33 → $40
Sep-05-17	Downgrade	SunTrust	Buy → Hold

Show Previous Ratings

Jul-25-24 04:30PM	FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment (GlobeNewswire) +12.20%
Jul-10-24 09:35AM	Down -22.78% in 4 Weeks, Here's Why You Should You Buy the Dip in Cellectis (CLLS) (Zacks)
Jul-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-28-24 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024 (GlobeNewswire)
Jun-20-24 04:30PM	Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing (GlobeNewswire)
12:00PM	Loading…
Jun-18-24 12:00PM	Cellectis (CLLS) Upgraded to Buy: Here's Why (Zacks) -5.84%
09:35AM	After Plunging -27.95% in 4 Weeks, Here's Why the Trend Might Reverse for Cellectis (CLLS) (Zacks)
Jun-12-24 04:30PM	Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications (GlobeNewswire)
Jun-05-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +6.23%
Jun-04-24 04:30PM	Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia (GlobeNewswire)
May-29-24 04:30PM	Cellectis' Annual Shareholders General Meeting to be Held on June 28, 2024 (GlobeNewswire)
May-28-24 08:52PM	CLLS Stock Earnings: Cellectis Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:30PM	Cellectis Reports Financial Results for First Quarter 2024 (GlobeNewswire)
May-27-24 04:30PM	Cellectis to Report First Quarter 2024 Financial Results on May 28, 2024 (GlobeNewswire)
May-16-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
04:30PM	Loading…
May-06-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +12.04% -7.46%
04:22AM	Cellectis Secures $140 Million Additional Equity Investment From AstraZeneca (MT Newswires)
02:00AM	Cellectis Announces Completion of the Additional Equity Investment by AstraZeneca (GlobeNewswire)
May-03-24 06:10AM	Cellectis CFO Bing Wang Retires, Interim CFO Appointed (MT Newswires)
May-02-24 04:30PM	Cellectis Appoints Arthur Stril as Interim Chief Financial Officer (GlobeNewswire) +17.90%
Apr-29-24 10:53PM	CLLS Stock Earnings: Cellectis Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace)
04:46PM	Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2023 (GlobeNewswire)
Apr-22-24 04:30PM	Cellectis Presents Novel TALEN Editing Processes Enabling Highly Efficient Gene Correction and Gene Insertion in HSPCs (GlobeNewswire)
Apr-10-24 04:30PM	Cellectis Publishes a Novel Intronic Gene Editing Approach For the Treatment of Inborn Metabolic Diseases by Edited HSPCs (GlobeNewswire)
Apr-08-24 04:30PM	Cellectis Announces Two Poster Presentations on Novel TALEN Editing Process for Gene Correction and Gene Insertion in HSPCs at the ASGCT Annual Meeting (GlobeNewswire)
Apr-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Mar-04-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Feb-02-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jan-16-24 04:30PM	Cellectis announces the drawdown of the second tranche of 15 million under the credit facility agreement entered with the European Investment Bank (EIB) (GlobeNewswire) -5.42%
Jan-08-24 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
04:30PM	Loading…
Dec-22-23 04:30PM	Cellectis Reports Results from Shareholders Meeting Held on December 22, 2023 (GlobeNewswire)
Dec-01-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -5.59%
Nov-17-23 04:30PM	Cellectis' Shareholders Meeting to be Held on December 22, 2023 (GlobeNewswire) +11.83% +5.80%
Nov-15-23 02:30AM	Cellectis Announces the execution of the Subsequent Investment Agreement with AstraZeneca (GlobeNewswire) +9.38%
Nov-06-23 04:30PM	Cellectis Reports Financial Results for Third Quarter and First Nine Months 2023 (GlobeNewswire) -13.41%
Nov-03-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Nov-02-23 04:30PM	Cellectis to Present Preliminary Results of NATHALI_01 and Updated Results of the BALLI_01 Phases I Trials at the American Society of Hematology (ASH) 65th Annual Meeting (GlobeNewswire) +14.02%
Nov-01-23 04:30PM	Cellectis to Report Third Quarter 2023 Financial Results on November 6, 2023 (GlobeNewswire) +172.16%
08:13AM	Why Is Cellectis (CLLS) Stock Up 175% Today? (InvestorPlace)
08:02AM	AstraZeneca takes 22% stake in Cellectis as part of collab for 10 cell and gene therapies (FierceBiotech.com)
03:00AM	Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca (GlobeNewswire)
Oct-31-23 04:30PM	Cellectis Presents Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Oct-24-23 04:30PM	Cellectis to Present Pre-Clinical Data on HSPC Gene Therapy Program and Comprehensive Analysis of TALE-BE at the ESGCT 30th Annual Congress (GlobeNewswire) -12.50%
Oct-12-23 04:30PM	Cellectis and Imagine Institute Publish A Proof-Of-Concept Study of a Gene Surgery Candidate to Treat Activated Phosphoinositide 3-Kinase Syndrome Type 1 (APDS1) (GlobeNewswire)
Oct-03-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -7.79%
09:55AM	These 2 Strong Buy Penny Stocks Could Gain Over 500%, Says Baird (TipRanks)
Sep-27-23 04:30PM	Cellectis to Present Pre-Clinical Data on Multi-armored Allogeneic MUC1-CAR T-cells Targeting Triple-Negative Breast Cancer at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting (GlobeNewswire)
Sep-05-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -8.96%
Aug-07-23 04:30PM	Cellectis Provides Full Report for Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 04:30PM	Cellectis Provides Business Updates and Preliminary Financial Results for Second Quarter 2023 (GlobeNewswire) -5.13%
Aug-01-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -6.07%
Jul-27-23 04:30PM	Cellectis to Report Second Quarter 2023 Financial Results on August 3, 2023 (GlobeNewswire)
Jul-12-23 04:30PM	Cellectis Appoints Dr. Cécile Chartier, Ph.D. to its Board of Directors (GlobeNewswire) +6.02%
Jun-28-23 04:30PM	Cellectis S.A. Reports Results from Annual Shareholders General Meeting Held on June 27, 2023 (GlobeNewswire)
Jun-13-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Jun-09-23 04:30PM	Cellectis Presents Updated Clinical and Translational Data on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire)
Jun-05-23 04:30PM	Cellectis Showcased Preclinical Data at an Oral Presentation and Two Poster Presentations at the 29th International Society for Cell & Gene Therapy (ISCT 2023) Annual Event (GlobeNewswire)
May-31-23 04:50PM	Cellectis Publishes an Article in Cancer Immunology Research Demonstrating Preclinical Evidence of UCART20x22 Product Candidate to Target a Broad Spectrum of Patients with B-cell Malignancies (GlobeNewswire)
May-17-23 04:30PM	Cellectis Presents Clinical Data on AMELI-01 and Preclinical Data on Multiplex Engineering for Superior Generation of CAR T-cells at ASGCT 2023 (GlobeNewswire)
May-12-23 01:30AM	Cellectis Publishes Article in Frontiers in Immunology Unveiling Pre-Clinical Data on a Novel Treatment Paradigm for Successful CAR T Immunotherapy Against Stroma-rich Solid Tumors (GlobeNewswire)
May-11-23 10:20AM	Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023 (GlobeNewswire) -5.73%
May-10-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
May-04-23 04:30PM	Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023 (GlobeNewswire)
May-02-23 04:35PM	Cellectis Announces Oral Presentation on AMELI-01 and Poster Presentation on Multiplex Engineering for Superior Generation of CAR T-cells at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting (GlobeNewswire) -6.41%
Apr-27-23 04:30PM	Cellectis to Report First Quarter 2023 Financial Results on May 4, 2023 (GlobeNewswire)
Apr-24-23 04:30PM	Cellectis Implements CLLS52 for the First Time in the Clinic with Sanofis Alemtuzumab (GlobeNewswire)
Apr-17-23 02:00AM	Cellectis Presents Preclinical Data on TALEN®-edited MUC1 CAR T-cells to Enhance Efficacy in Targeting Triple Negative Breast Cancer at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Apr-12-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire)
Apr-11-23 04:30PM	Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22 (GlobeNewswire)
Apr-04-23 04:30PM	Cellectis enters into warrant agreement with the European Investment Bank related to credit facility agreement and announces the drawdown of the first tranche of 20 million (GlobeNewswire)
Mar-15-23 05:02PM	Monthly information on share capital and company voting rights (GlobeNewswire) -7.58%
Mar-14-23 05:00PM	Cellectis Announces Poster Presentation on TALEN®-edited MUC1 CAR T-cells Targeting Triple Negative Breast Cancer at the American Association of Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Mar-08-23 04:45PM	Cellectis Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
Mar-06-23 04:30PM	Calyxt, Inc. Reports its Fourth Quarter 2022 Financial Results and Provides Corporate Update (GlobeNewswire)
Mar-01-23 04:30PM	Cellectis to Report Fourth Quarter and Year-End 2022 Financial Results on March 8, 2023 (GlobeNewswire)
Feb-09-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +5.43%
Feb-07-23 07:01PM	Cellectis Announces Closing of Global Offering and Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -5.46%
Feb-03-23 09:33AM	Cellectis Supplements the Announcement of the Pricing of Follow-On Offering with Allocation of Share Capital Information (GlobeNewswire) -23.01%
12:48AM	Cellectis Announces Pricing of Follow-On Offering (GlobeNewswire)
Feb-02-23 04:01PM	Cellectis Announces Launch of Follow-On Offering (GlobeNewswire) +5.16%
Jan-30-23 07:10PM	7 CRISPR Stocks With the Best Long-Term Potential (InvestorPlace)
Jan-20-23 04:30PM	Cellectis Amends $20 Million Convertible Note Under Collaboration Agreement with its Partner Cytovia Therapeutics (GlobeNewswire) +10.46%
Jan-17-23 07:10AM	Calyxt and Cibus Announce the Signing of a Definitive Merger Agreement (GlobeNewswire) -11.98%
Jan-09-23 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) +18.73% +5.06%
Jan-04-23 05:08PM	Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq (GlobeNewswire) +7.56%
Dec-29-22 04:30PM	Mayflower Bioventures Launches its First Spin-Out, Primera Therapeutics, in Strategic Collaboration with Cellectis to Develop a Gene Editing Platform to Treat Mitochondrial Diseases (GlobeNewswire) +5.41% +7.69%
Dec-28-22 04:30PM	Cellectis secures a 40 million credit facility from the European Investment Bank to support its Research, Development and Innovation activities (GlobeNewswire)
Dec-22-22 04:30PM	Cellectis Announces First Dosing of a Patient with its In-house Manufactured Product Candidate UCART22 for the treatment of r/r B-cell ALL (GlobeNewswire)
Dec-16-22 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -9.78% -6.40%
Dec-13-22 01:47PM	Cellectis Touts Positive Preliminary Data From Two Leukemia Trials (Benzinga)
07:30AM	Cellectis Announces Positive Preliminary Clinical Data for UCART22 in ALL and UCART123 in AML (GlobeNewswire)
Dec-01-22 04:40PM	Cellectis to Host a Live Webcast and Provide a Company Update on December 13, 2022 (GlobeNewswire)
Nov-10-22 09:05AM	Cellectis Presents Pre-Clinical Data on TALEN®-edited Smart CAR T-cells Overcoming Key Challenges of Targeting Solid Tumors at SITC 2022 (GlobeNewswire) +12.56%
02:48AM	Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology Unveiling Efficient Multitool/Multiplex Gene Engineering combining TALEN® and TALE Base Editors (TALE-BE) (GlobeNewswire)
Nov-08-22 04:30PM	Monthly information on share capital and company voting rights (GlobeNewswire) -9.61%
Nov-04-22 12:31PM	Iovance's (IOVA) Q3 Earnings Beat Estimates, Revenues Nil (Zacks)
Nov-03-22 04:36PM	Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2022 (GlobeNewswire)
04:05PM	Cellectis to Showcase Clinical Data from AMELI-01 and Preclinical Data from UCARTCS1 at ASH 2022 (GlobeNewswire)
Oct-27-22 04:37PM	Cellectis to Report Third Quarter 2022 Financial Results (GlobeNewswire)
Oct-11-22 04:30PM	Cellectis Presents Data on Two TALEN®-based Gene Therapy Preclinical Programs for Patients with Sickle Cell Disease and Mucopolysaccharidosis type I at ESGCT 2022 (GlobeNewswire)

Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company was founded by David J. Sourdive and Andre Choulika on February 20, 1999 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLLS

Cellectis ADR

Upgrade your FINVIZ experience